Nimotuzumab for the first line treatment of metastatic pancreatic cancer
Please note that this appraisal has now been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- STA Standard
- ID number:
- 513
Provisional Schedule
- Closing date for invited submissions / evidence submission::
- TBC
- 1st appraisal committee meeting::
- TBC
Project Team
- Executive Lead:
- TBC
- Project manager:
- Technical Lead:
- TBC
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 08 January 2024 | Discontinued. Please note that this appraisal has now been discontinued. |
| 19 September 2014 | Following on from advice received from the manufacturer, the dates for this appraisal will be confirmed once regulatory approval timelines are established. |
For further information on our processes and methods, please see our CHTE processes and methods manual